Factors associated with emotional distress in newly-diagnosed prostate cancer identified

Share this content:

the ONA take:

According to a new study published in the journal Psycho-Oncology, researchers from the University at Buffalo Department of Community Health and Health Behavior in Buffalo, New York, have identified certain factors associated with emotional distress in men with newly diagnosed prostate cancer.

For the study, researchers sought to identify factors associated with significant emotional distress in men with newly diagnosed prostate cancer so that may identify acceptable intervention strategies to manage that distress. 

Researchers identified 1,425 men with newly diagnosed clinically localized prostate cancer who had not received treatment for their disease yet.

Participants used the Distress Thermometer to report how much distress they were experiencing and identify what problems they experienced in the past week. Results showed that low self-efficacy for decision-making, low confidence in cancer control, masculine identity threat, low optimism, and low resilience were associated with higher emotional distress.

The findings suggest that improving communication about prostate cancer prognosis, providing decision-making support, and referring to brief cognitive behavioral interventions may be useful approaches at mitigating significant emotional distress for those with newly diagnosed prostate cancer.

Study investigating advanced MRI scans to detect prostate cancer set to begin
Researchers identified certain factors associated with emotional distress in men with newly diagnosed prostate cancer.
The authors sought to identify factors that are associated with distress in these men as a basis for identifying suitable intervention strategies. Findings provide a framework for the development of interventions for prostate cancer patients with elevated emotional distress.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs